The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 12, 2016, Pages 4500-4511

  Brown, Rebecca J ^a   Araujo Vilar, David ^b   Cheung, Pik To ^c   Dunger, David ^d,e   Garg, Abhimanyu ^f   Jack, Michelle ^g   Mungai, Lucy ^h   Oral, Elif A ⁱ   Patni, Nivedita ^j   Rother, Kristina I ^a   Von Schnurbein, Julia ^k   Sorkina, Ekaterina ^l   Stanley, Takara ^m   Vigouroux, Corinne ⁿ   Wabitsch, Martin ^k   Williams, Rachel ^o   Yorifuji, Tohru ^p  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY OF NAIROBI   (Kenya)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF ULM   (Germany)

^l MOSCOW STATE UNIVERSITY   (Russian Federation)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^p OSAKA CITY GENERAL HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; CHOLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN DERIVATIVE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; METRELEPTIN; PIOGLITAZONE;

ARTICLE; BARRAQUER SIMONS SYNDROME; CLINICAL FEATURE; COMORBIDITY; CONGENITAL GENERALIZED LIPODYSTROPHY; DIABETES MELLITUS; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DYSLIPIDEMIA; FAMILIAL PARTIAL LIPODYSTROPHY; FAMILY STUDY; GENETIC COUNSELING; GENETIC SCREENING; GENITAL SYSTEM DISEASE; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE URTICARIA; KIDNEY DISEASE; KINESIOTHERAPY; LAWRENCE SYNDROME; LEPTIN DEFICIENCY; LIPODYSTROPHY; LIPODYSTROPHY SYNDROME; LIVER DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EXPERT; MEDICAL SOCIETY; METABOLIC DISORDER; PHENOTYPE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; SYNDROME; TREATMENT RESPONSE;

HUMANS; LIPODYSTROPHY; PRACTICE GUIDELINES AS TOPIC;

EID: 85003601739     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2466     Document Type: Article

References (114)

1. Brown RJ, Gorden P. Leptin therapy in patients with lipodystrophy and syndromic insulin resistance. In: Dagogo-Jack S, ed. Leptin: Regulation and Clinical Applications. Cham, Switzerland: Springer International Publishing; 2015:225-236
2. PG, Semb BK, Trygstad O, Seip M. Echocardiographic assessment of cardiac function and morphology in patients with generalised lipodystrophy. Eur J Pediatr. 1985;144(4):355-359
3. Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: A clinical assessment. Medicine (Baltimore). 2010;89(4):245-250
4. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: Case reports and review of the literature. Medicine (Baltimore). 2003;82(2):129-146
5. Jackson SN, Howlett TA, McNally PG, O'Rahilly S, Trembath RC. Dunnigan-Kobberling syndrome: An autosomal dominant form of partial lipodystrophy. QJM. 1997;90(1):27-36
6. Seip M. Generalized lipodystrophy. In: Frick P, von Harnack GA, Muller AF, Prader A, Schoen R, Wolff HP, eds. Ergebnisse der Inneren Medizin und Kinderheilkunde. Berlin, Germany: Springer; 1971:59-95
7. Garg A. Clinical review: Lipodystrophies: Genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313-3325
8. Gibbons RJ, Smith S, Antman E, et al. American College of Cardiology/American Heart Association clinical practice guidelines. Part I: where do they come from?. Circulation. 2003;107(23): 2979-2986
9. Agarwal AK, Simha V, Oral EA, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab. 2003;88(10):4840-4847
10. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220-1234
11. Hayashi YK, Matsuda C, OgawaM, et al.HumanPTRFmutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest. 2009;119(9): 2623-2633
12. Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin Endocrinol Metab. 2003;88(11):5433-5437
13. Van Maldergem L, J, Khallouf TE, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet. 2002;39(10):722-733
14. Vantyghem MC, Vincent-Desplanques D, Defrance-Faivre F, et al. Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy. J Clin Endocrinol Metab. 2008;93(6):2223-2229
15. Hegele RA. Premature atherosclerosis associated with monogenic insulin resistance. Circulation. 2001;103(18):2225-2229
16. Savage DB, Semple RK, Clatworthy MR, et al. Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab. 2009;94(1):10-16
17. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: Report of 35 cases and review of the literature. Medicine (Baltimore). 2004;83(1):18-34
18. Handelsman Y, Oral EA, Bloomgarden ZT, et al. The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract. 2013;19(1):107-116
19. Safar Zadeh E, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: The long-term effect of leptin treatment. J Hepatol. 2013;59(1):131-137
20. Pope E, Janson A, Khambalia A, Feldman B. Childhood acquired lipodystrophy: A retrospective study. J Am Acad Dermatol. 2006; 55(6):947-950
21. Garg A. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 2000;85(5):1776-1782
22. Savage DB, Soos MA, Powlson A, et al. Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene. Diabetologia. 2004;47(4):753-756
23. Decaudain A, Vantyghem MC, Guerci B, et al. New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. J Clin Endocrinol Metab. 2007; 92(12):4835-4844
24. Park JY, Chong AY, Cochran EK, et al. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: The effect of long-term leptin therapy. J Clin Endocrinol Metab. 2008; 93(1):26-31
25. Brown RJ, Meehan CA, Gorden P. Leptin does not mediate hypertension associated with human obesity. Cell. 2015;162(3):465-466
26. Ben Turkia H, Tebib N, Azzouz H, et al. [Congenital generalized lipodystrophy: A case report with neurological involvement [in French]. Arch Pediatr. 2009(1);16:27-31
27. Debray FG, Baguette C, Colinet S, Van Maldergem L, Verellen-Dumouin C. Early infantile cardiomyopathy and liver disease: A multisystemic disorder caused by congenital lipodystrophy. Mol Genet Metab. 2013;109(2):227-229
28. A-Vilar D, Lado-Abeal J, Palos-Paz F, et al. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy. Clin Endocrinol (Oxf). 2008;69(1):61-68
29. Bhayana S, Siu VM, Joubert GI, Clarson CL, Cao H, Hegele RA. Cardiomyopathy in congenital complete lipodystrophy. Clin Genet. 2002;61(4):283-287
30. Caux F, Dubosclard E, Lascols O, et al. A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J Clin Endocrinol Metab. 2003;88(3):1006-1013
31. Khalife WI, Mourtada MC, Khalil J. Dilated cardiomyopathy and myocardial infarction secondary to congenital generalized lipodystrophy. Tex Heart Inst J. 2008;35(2):196-199
32. Rheuban KS, Blizzard RM, Parker MA, Carter T, Wilson T, Gutgesell HP. Hypertrophic cardiomyopathy in total lipodystrophy. J Pediatr. 1986;109(2):301-302
33. Andre P, Schneebeli S, Vigouroux C, Lascols O, Schaaf M, Chevalier P. Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A. Am Heart J. 2015;169(4):587-593
34. Javor ED, Moran SA, Young JR, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: Baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004;89(7):3199-3207
35. Brown RJ, Chan JL, Jaffe ES, et al. Lymphoma in acquired generalized lipodystrophy. Leuk Lymphoma. 2016;57(1):45-50
36. Patni N, Alves C, von Schnurbein J, et al. A novel syndrome of generalized lipodystrophy associated with pilocytic astrocytoma. J Clin Endocrinol Metab. 2015;100(10):3603-3606
37. Robbins DC, Danforth E Jr, Horton ES, Burse RL, Goldman RF, Sims EA. The effect of diet on thermogenesis in acquired lipodystrophy. Metabolism. 1979;28(9):908-916
38. Glueck CJ, Mellies MJ, Tsang RC, Kashyap ML, Steiner PM. Familial hypertriglyceridemia in children: Dietary management. Pediatr Res. 1977;11(9 Pt 1):953-957
39. Wilson DE, Chan IF, Stevenson KB, Horton SC, Schipke C. Eucaloric substitution of medium chain triglycerides for dietary long chain fatty acids in acquired total lipodystrophy: Effects on hyperlipoproteinemia and endogenous insulin resistance. J Clin Endocrinol Metab. 1983;57(3):517-523
40. Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol. 2016;9(1):59-68
41. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570-578
42. Ebihara K, Kusakabe T, Hirata M, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007;92(2):532-541
43. MoranSA, Patten N, YoungJR, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004;53(4):513-519
44. McDuffie JR, Riggs PA, Calis KA, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab. 2004;89(9):4258-4263
45. Musso C, Cochran E, Javor E, Young J, Depaoli AM, Gorden P. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism. 2005;54(2):255-263
46. Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: Comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015;100(5): 1802-1810
47. Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011;17(6):922-932
48. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010;53(1):27-35
49. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology. 2005;41(4):753-760
50. Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care. 2003;26(1):30-35
51. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest. 2002;109(10):1345-1350
52. Casey SP, Lokan J, Testro A, et al. Post-liver transplant leptin results in resolution of severe recurrence of lipodystrophy-associated nonalcoholic steatohepatitis. Am J Transplant. 2013(11);13: 3031-3034
53. Oral EA, Ruiz E, Andewelt A, et al. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab. 2002;87(7):3110-3117
54. Abel BS, Muniyappa R, Stratton P, Skarulis MC, Gorden P, Brown RJ. Effects of recombinant human leptin (metreleptin) on nocturnal secretion in lipodystrophy patients. Neuroendocrinology. 2016;103(3-4):402-407
55. Lungu AO, Zadeh ES, Goodling A, Cochran E, Gorden P. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2012;97(2):563-567
56. Vatier C, Fetita S, Boudou P, et al. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes Metab. 2016;18(7):693-697
57. Simha V, Subramanyam L, Szczepaniak L, et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2012;97(3): 785-792
58. Beltrand J, Lahlou N, Le Charpentier T, et al. Resistance to leptinreplacement therapy in Berardinelli-Seip congenital lipodystrophy: An immunological origin. Eur J Endocrinol. 2010;162(6):1083-1091
59. Chan JL, Koda J, Heilig JS, et al. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Clin Endocrinol (Oxf). 2016;85(1):137-149
60. Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med. 2000;133(4):263-274
61. Luedtke A, Boschmann M, Colpe C, et al. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: A case series. Horm Metab Res. 2012;44(4):306-311
62. Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: Is it time for U-500 insulin?. Endocr Pract. 2009;15(1):71-79
63. Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med. 2005;22(10):1444-1445
64. Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356(9228): 443-445
65. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934
66. Catapano AL, Chapman J, Wiklund O, Taskinen MR. The new joint EAS/ESC guidelines for the management of dyslipidaemias. Atherosclerosis. 2011;217(1):1
67. Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012; 18(suppl 1):1-78
68. Settergren J, Eiermann B, Mannheimer B. Adherence to drug label recommendations for avoiding drug interactions causing statininduced myopathy- A nationwide register study. PLoS One. 2013; 8(8):e69545
69. Bolan C, Oral EA, Gorden P, Taylor S, Leitman SF. Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. J Clin Endocrinol Metab. 2002;87(1):380-384
70. American Diabetes Association. Standards of medical care in diabetes-2016 abridged for primary care providers. Clin Diabetes. 2016;34(1):3-21
71. Ahmad Z, Subramanyam L, Szczepaniak L, Simha V, Adams-Huet B, Garg A. Cholic acid for hepatic steatosis in patients with lipodystrophy: A randomized, controlled trial. Eur J Endocrinol. 2013; 168(5):771-778
72. Mitchel EB, Lavine JE. Review article: The management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1155-1170
73. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.NEngl JMed. 2010; 362(18):1675-1685
74. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA. 2011;305(16):1659-1668
75. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Metaanalysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35(1):66-75
76. Graivier MH, Bass LS, Busso M, Jasin ME, Narins RS, Tzikas TL. Calcium hydroxylapatite (Radiesse) for correction of the mid- and lower face: Consensus recommendations. Plast Reconstr Surg. 2007;120(6 suppl):55S-66S.
77. Hurwitz PJ, Sarel R. Facial reconstruction in partial lipodystrophy. Ann Plast Surg. 198(3)2;8:253-257
78. Calderoni DR, Ramos TM, de Castro JR, Kharmandayan P. Surgical management of phenotypic alterations related to the Dunnigan variety of familial partial lipodystrophy. J Plast Reconstr Aesthet Surg. 2011;64(9):1248-1250
79. Hughes JM, Stephen C, Johnson AB, Wilson S. Breast augmenta- tion in familial partial lipodystrophy: A case report. J Plast Reconstr Aesthet Surg. 2011;64(5):e121-e124
80. Araujo-Vilar D, -Amarelle C, et al. Recombinant human leptin treatment in genetic lipodystrophic syndromes: The long-term Spanish experience. Endocrine. 2015;49(1):139-147
81. Eberting CL, Javor E, Gorden P, Turner ML, Cowen EW. Insulin resistance, acanthosis nigricans, and hypertriglyceridemia. J Am Acad Dermatol. 2005;52(2):341-344
82. Loriaux DL. An approach to the patient with hirsutism. J Clin Endocrinol Metab. 2012;97(9):2957-2968
83. WalshBW, Schiff I, Rosner B, Greenberg L, Ravnikar V, SacksFM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.NEngl J Med. 1991; 325(17):1196-1204
84. Agarwal AK, Arioglu E, De Almeida S, et al. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet. 2002;31(1):21-23
85. M, Khallouf E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28(4):365-370
86. Kim CA, Delpine M, Boutet E, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93(4):1129-1134
87. Payne F, Lim K, Girousse A, et al. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. Proc Natl Acad SciUSA. 2014; 111(24):8901-8906
88. Dyment DA, Gibson WT, Huang L, Bassyouni H, Hegele RA, Innes AM. Biallelic mutations at PPARG cause a congenital, generalized lipodystrophy similar to the Berardinelli-Seip syndrome. Eur J Med Genet. 2014;57(9):524-526
89. Novelli G, Muchir A, Sangiuolo F, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C.AmJ Hum Genet. 2002;71(2):426-431
90. AgarwalAK, Fryns JP, Auchus RJ, Garg A. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet. 2003;12(16):1995-2001
91. Lessel D, Vaz B, Halder S, et al. Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features. Nat Genet. 2014;46(11):1239-1244
92. Donadille B, D'Anella P, Auclair M, et al. Partial lipodystrophy with severe insulin resistance and adult progeria Werner syndrome. Orphanet J Rare Dis. 2013;8:106
93. Cabanillas R, Cadianos J, Villameytide JA, et al. Nstor-Guillermo progeria syndrome: A novel premature aging condition with early onset and chronic development caused by BANF1 mutations.AmJ Med Genet A. 2011;155A(11):2617-2625
94. Rubio-Cabezas O, Puri V, Murano I, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med. 2009;1(5):280-287
95. Albert JS, Yerges-Armstrong LM, Horenstein RB, et al. Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. N Engl J Med. 2014;370(24):2307-2315
96. Farhan SM, Robinson JF, McIntyre AD, et al. A novel LIPE nonsense mutation found using exome sequencing in siblings with lateonset familial partial lipodystrophy. Can J Cardiol. 2014;30(12): 1649-1654
97. Agarwal AK, Xing C, DeMartino GN, et al. PSMB8 encoding the -5i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet. 2010;87(6):866-872
98. Herbst KL, Tannock LR, Deeb SS, Purnell JQ, Brunzell JD, Chait A. Kbberling type of familial partial lipodystrophy: An underrecognized syndrome. Diabetes Care. 2003;26(6):1819-1824
99. Cao H, Hegele RA. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000;9(1):109-112
100. Shackleton S, Lloyd DJ, Jackson SN, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet. 2000;24(2): 153-156
101. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPAR- associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402(6764): 880-883
102. George S, Rochford JJ, Wolfrum C, et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004;304(5675):1325-1328
103. Gandotra S, LeDourC, BottomleyW, et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med. 2011; 364(8):740-748
104. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423(6937):293-298
105. De Sandre-Giovannoli A, Bernard R, Cau P, et al. Lamin a truncation in Hutchinson-Gilford progeria. Science. 2003;300(5628): 2055
106. Graul-Neumann LM, Kienitz T, Robinson PN, et al. Marfan syndrome with neonatal progeroid syndrome-like lipodystrophy associated with a novel frameshift mutation at the 3- terminus of the FBN1-gene. Am J Med Genet A. 2010;152A(11):2749-2755
107. Garg A, Kircher M, Del Campo M, et al. Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. Am J Med Genet A. 2015;167A(8):1796-1806
108. WeedonMN, Ellard S, Prindle MJ, et al.Anin-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet. 2013;45(8):947-950
109. Masotti A, Uva P, Davis-Keppen L, et al. Keppen-Lubinsky syndrome is caused by mutations in the inwardly rectifying K- channel encoded by KCNJ6. Am J Hum Genet. 2015;96(2):295-300
110. Thauvin-Robinet C, Auclair M, Duplomb L, et al. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. Am J Hum Genet. 2013;93(1):141-149
111. Aotani D, Ebihara K, Sawamoto N, et al. Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy. J Clin Endocrinol Metab. 2012;97(10):3663-3671
112. Panchal R, Bosio P, Waugh J. Familial partial lipodystrophy complicated by pre-eclampsia. J Obstet Gynaecol. 2005;25(2):196-197
113. Ldtke A, Genschel J, Brabant G, et al. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am J Gastroenterol. 2005;100(10):2218-2224
114. Peters DK, Charlesworth JA, Sissons JG, et al. Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia. Lancet. 1973;2(7828):535-538